119 related articles for article (PubMed ID: 8335152)
1. Protracted clinical course for patients with Canavan disease.
Zelnik N; Luder AS; Elpeleg ON; Gross-Tsur V; Amir N; Hemli JA; Fattal A; Harel S
Dev Med Child Neurol; 1993 Apr; 35(4):355-8. PubMed ID: 8335152
[TBL] [Abstract][Full Text] [Related]
2. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease.
Matalon R; Michals K; Sebesta D; Deanching M; Gashkoff P; Casanova J
Am J Med Genet; 1988 Feb; 29(2):463-71. PubMed ID: 3354621
[TBL] [Abstract][Full Text] [Related]
3. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease.
Divry P; Mathieu M
Am J Med Genet; 1989 Apr; 32(4):550-1. PubMed ID: 2774002
[No Abstract] [Full Text] [Related]
4. N-acetylaspartic aciduria in Canavan disease: another proof in two infants.
Yalaz K; Topçu M; Topaloğlu H; Gürçay O; Ozcan OE; Onol B; Renda Y
Neuropediatrics; 1990 Aug; 21(3):140-2. PubMed ID: 2234319
[TBL] [Abstract][Full Text] [Related]
5. Spongy degeneration of the neuraxis (Canavan-van Bogaert disease) and N-acetylaspartic aciduria.
Echenne B; Divry P; Vianey-Liaud C
Neuropediatrics; 1989 May; 20(2):79-81. PubMed ID: 2739878
[TBL] [Abstract][Full Text] [Related]
6. Canavan disease: value of N-acetylaspartic aciduria?
de Coo IF; Bakkeren JA; Gabreëls FJ
Neuropediatrics; 1991 May; 22(2):III. PubMed ID: 1857492
[No Abstract] [Full Text] [Related]
7. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
[TBL] [Abstract][Full Text] [Related]
8. The spectrum of mutations of the aspartoacylase gene in Canavan disease in non-Jewish patients.
Elpeleg ON; Shaag A
J Inherit Metab Dis; 1999 Jun; 22(4):531-4. PubMed ID: 10407784
[TBL] [Abstract][Full Text] [Related]
9. Canavan disease: diagnosis and molecular analysis.
Matalon R
Genet Test; 1997; 1(1):21-5. PubMed ID: 10464621
[TBL] [Abstract][Full Text] [Related]
10. Biochemical diagnosis of Canavan disease.
Bartalini G; Margollicci M; Balestri P; Farnetani MA; Cioni M; Fois A
Childs Nerv Syst; 1992 Dec; 8(8):468-70. PubMed ID: 1288858
[TBL] [Abstract][Full Text] [Related]
11. A case of Canavan disease: the first biochemically proven case in a Japanese girl.
Hamaguchi H; Nihei K; Nakamoto N; Ezoe T; Naito H; Hara M; Yokota K; Inoue Y; Matsumoto I
Brain Dev; 1993; 15(5):367-71. PubMed ID: 8279652
[TBL] [Abstract][Full Text] [Related]
12. [N-acetylaspartic aciduria. Clinical, biological and physiopathological study].
Gay C; Divry P; Macabeo V; Gilly R
Arch Fr Pediatr; 1991; 48(6):409-13. PubMed ID: 1929728
[TBL] [Abstract][Full Text] [Related]
13. Variable course of Canavan disease in two boys with early infantile aspartoacylase deficiency.
von Moers A; Sperner J; Michael T; Scheffner D; Schutgens RH
Dev Med Child Neurol; 1991 Sep; 33(9):824-8. PubMed ID: 1936635
[TBL] [Abstract][Full Text] [Related]
14. Canavan disease: findings in four new cases.
Michelakakis H; Giouroukos S; Divry P; Katsarou E; Rolland MO; Skardoutsou A
J Inherit Metab Dis; 1991; 14(2):267-8. PubMed ID: 1886410
[No Abstract] [Full Text] [Related]
15. Protracted course of N-acetylaspartic aciduria in two non-Jewish siblings: identical clinical and magnetic resonance imaging findings.
Zafeiriou DI; Kleijer WJ; Maroupoulos G; Anastasiou AL; Augoustidou-Savvopoulou P; Papadopoulou F; Kontopoulos EE; Fagan E; Payne S
Brain Dev; 1999 Apr; 21(3):205-8. PubMed ID: 10372908
[TBL] [Abstract][Full Text] [Related]
16. N-acetylaspartic aciduria due to aspartoacylase deficiency--a new aetiology of childhood leukodystrophy.
Hagenfeldt L; Bollgren I; Venizelos N
J Inherit Metab Dis; 1987; 10(2):135-41. PubMed ID: 3116332
[TBL] [Abstract][Full Text] [Related]
17. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of Canavan disease.
Matalon R; Michals-Matalon K
Eur J Paediatr Neurol; 1998; 2(2):69-76. PubMed ID: 10724099
[No Abstract] [Full Text] [Related]
19. Stable isotope dilution analysis of N-acetylaspartic acid in CSF, blood, urine and amniotic fluid: accurate postnatal diagnosis and the potential for prenatal diagnosis of Canavan disease.
Jakobs C; ten Brink HJ; Langelaar SA; Zee T; Stellaard F; Macek M; Srsnová K; Srsen S; Kleijer WJ
J Inherit Metab Dis; 1991; 14(5):653-60. PubMed ID: 1779610
[TBL] [Abstract][Full Text] [Related]
20. Canavan disease: from spongy degeneration to molecular analysis.
Matalon R; Michals K; Kaul R
J Pediatr; 1995 Oct; 127(4):511-7. PubMed ID: 7562269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
